Invention by Howard J. Leonhardt is assigned to Leonhardt Ventures LLC and licensed to Lionheart Health, Inc., expanding a bioelectric inflammation-management platform
HUNTINGTON BEACH, Calif. — Leonhardt Ventures LLC and Lionheart Health, Inc. today announced the filing of a provisional patent application directed to bioelectric downregulation of interleukin-11, or IL-11, an inflammatory signaling protein implicated in fibrosis, metabolic dysfunction, and age-related physical decline.
The proposed platform will investigate whether carefully selected electrical stimulation signals can reduce excessive endogenous IL-11 expression, release, or associated signaling. The research objective is to develop measurable, adjustable approaches to managing age-associated inflammation while preserving biological functions necessary for normal tissue maintenance and repair.
Building on Published Longevity Research
The scientific rationale includes research published in Nature on July 17, 2024, titled “Inhibition of IL-11 signalling extends mammalian healthspan and lifespan.” Investigators affiliated with Duke-NUS Medical School and the MRC Laboratory of Medical Sciences, among other institutions, reported that blocking IL-11 improved several measures of health in aging mice.
In the antibody-treatment experiments, treatment beginning at 75 weeks of age increased median lifespan by 22.5% in male mice and 25% in female mice. The researchers also reported improvements in metabolic and muscle-related measures. These findings concern genetic deletion and antibody-mediated inhibition in mice; they do not demonstrate that bioelectric stimulation suppresses IL-11 or extends human lifespan. (nature.com)
Leonhardt Ventures’ proposed approach seeks to investigate a different means of influencing this biological target: programmable bioelectric stimulation, with laboratory confirmation of target engagement before clinical translation.
Extending Leonhardt’s Existing Inflammation Patent Platform
The new filing builds on the technological direction described in Leonhardt’s issued U.S. Patent No. 11,110,274, “System and method for treating inflammation,” and its related published disclosures.
That patent describes sensing inflammation and adjusting bioelectric signals to regulate protein expression and release. Its named inflammation and repair mediators include IL-1β, IL-6, IL-10, TNF-α, TGF-β, IGF1, and CXCL5. Additional expression-related discussions include IL-8, CCL2, MMP9, CXCL1, CXCL3, CXCL9, and CXCL10, with IFN-γ discussed in inflammatory regulation.
Associated repair and vascular signaling discussions include SDF-1/CXCR4, VEGF, PDGF, eNOS, HGF, GDF10, activin, and BDNF/TrkB. These molecules have different biological roles; their appearance in a patent does not establish equivalent claim coverage or validated therapeutic control.
The earlier disclosure emphasizes timing, location, and balance, including sequences intended to increase and subsequently inhibit selected inflammatory signals. IL-11 was not explicitly identified in the reviewed U.S. patent text. The new application adds an express focus on IL-11 downregulation and its potential relationship to age-associated dysfunction. (patents.google.com, patents.google.com, patents.google.com, patents.google.com, patents.google.com)
Research Priorities
The development program is intended to evaluate:
- Whether selected bioelectric waveforms reproducibly reduce IL-11 expression or release in relevant cell and tissue models.
- Whether observed effects reflect specific biological regulation rather than cell injury or nonspecific suppression.
- Relationships between IL-11 modulation, fibrosis markers, cellular senescence, and metabolic signaling.
- Potential applications involving skeletal muscle, adipose tissue, liver, kidneys, heart, and other tissues affected by aging.
- Feedback-guided stimulation using measured biological responses to adjust treatment parameters.
- Whether an IL-11-directed approach could eventually complement Lionheart Health’s broader Klotho-focused healthspan research.
Initial studies would compare active stimulation with appropriate sham controls and established laboratory comparators. Any subsequent human investigation would require supporting preclinical evidence, appropriate regulatory review, and applicable ethics approvals.
About Leonhardt Ventures LLC
Founded in 1982, Leonhardt Ventures LLC develops technologies in bioelectric medicine, regenerative medicine, cardiovascular care, and healthspan research. Its development approach includes programmable stimulation intended to influence selected biological signals and tissue responses.
About Lionheart Health, Inc.
Lionheart Health, Inc. develops and commercializes technologies and programs involving bioelectric stimulation, regenerative medicine, and healthspan research. The company’s research interests include muscle function, brain health, immune and metabolic function, and Klotho-associated biology.
Scientific, Regulatory, and Intellectual Property Notice
The IL-11 bioelectric platform is investigational. No validated IL-11-suppressing electrical waveform or human longevity benefit is announced in this release. Animal findings may not translate to humans. Neither the cited research nor the provisional filing establishes that this approach is safe or effective for treating disease, preventing cancer, reversing aging, or extending human lifespan.
A provisional patent application is not an issued patent. Any future patent protection depends on subsequent filings, examination, and applicable legal requirements. Patentability and freedom to operate are separate questions.
Forward-Looking Statements
This release contains forward-looking statements concerning research plans, potential applications, intellectual property, development, and commercialization. Actual outcomes may differ materially because of scientific uncertainty, inability to demonstrate target engagement, safety findings, regulatory requirements, third-party intellectual property, funding limitations, and other development risks. No assurance is provided that a product will receive regulatory authorization or reach commercialization.
Scientific reference: Widjaja AA et al. “Inhibition of IL-11 signalling extends mammalian healthspan and lifespan.” Nature. 2024;632:157–165. doi:10.1038/s41586-024-07701-